Investors of Medpace Remembered to Act Before Class Action Deadline on June 8, 2026

Medpace Investors Alerted About Class Action Deadline

Faruqi & Faruqi, LLP, a recognized leader in securities law, is reaching out to investors of Medpace Holdings, Inc. regarding an important upcoming deadline. Investors who acquired shares of Medpace between April 22, 2025, and February 9, 2026, are encouraged to take note of a significant date: June 8, 2026. This date marks the last chance for shareholders to seek the role of lead plaintiff in a federal class action lawsuit filed against the company.

The firm has initiated this investigation due to concerns about misleading information disseminated by Medpace's management. During the aforementioned timeline, investors received consistently optimistic outlooks from the company, which were at odds with underlying operational realities. Notably, Medpace officials previously claimed that their backlog cancellation rates were manageable, characterizing them as 'well behaved'. However, they did not disclose the true impact of these cancellations on the company’s financial health.

On February 9, 2026, the situation took a turn when Medpace disclosed its fourth-quarter results. The book-to-bill ratio reported was a mere 1.04, significantly lower than the anticipated 1.15. The immediate aftermath of this release saw Medpace's stock plummet from $530.35 to $446.05—a drop of over 15.9% in just one day. This astonishing decline has raised red flags for investors who may have been misled about the company's growth prospects.

Faruqi & Faruqi’s co-founder and senior partner, Josh Wilson, has been vocal about the interests of Medpace investors, suggesting that those financially affected reach out to the firm directly for guidance. The legal options available include participating as a lead plaintiff, which entails directing the litigation on behalf of other investors, or opting to remain a passive class member. Importantly, choosing to take part in the lead plaintiff role does not impact the investor's eligibility to benefit from any potential recovery.

The law firm encourages any individuals with inside information regarding Medpace's practices or who believe they have pertinent information, including former employees or whistleblowers, to step forward and share their insights. Transparency in these matters is essential not just for the integrity of Medpace's operations but also for the trust and protection of its investors.

For those interested in pursuing legal action or seeking more information about the Medpace class action, they can visit www.faruqilaw.com/MEDP or contact Josh Wilson at 877-247-4292 (ext. 1310) or 212-983-9330. As the June deadline looms, prompt action will be necessary for those wishing to safeguard their rights under the law.

Faruqi & Faruqi, LLP has an extensive track record since its inception in 1995, successfully securing hundreds of millions of dollars for investors. By fostering a proactive approach to legal representation, the firm aims to ensure that investors do not navigate these complex situations alone.

Investors should remain vigilant and informed, as the repercussions from the latest developments at Medpace could have significant implications for those involved. Keeping abreast of updates and responding swiftly can make all the difference in protecting one’s financial interests.